Saúde Pública/Medicina Humanitária

Revisão sistemática | Como a redução das horas de trabalho pode influenciar os desfechos de saúde.

11 Abr, 2022 | 12:31h

How the reduction of working hours could influence health outcomes: a systematic review of published studies – BMJ Open

---

Revisão sistemática | Abordagens e resultados de intervenções de profissionais da saúde na comunidade para manejo e controle da hipertensão em países de baixa e média rendas.

11 Abr, 2022 | 12:30h

Approaches and outcomes of community health worker’s interventions for hypertension management and control in low-income and middle-income countries: systematic review – BMJ Open

---

COVID-19: diretriz conjunta do ECDC e EMA sobre a 4ª dose de vacinas de mRNA.

8 Abr, 2022 | 21:56h

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines –
European Centre for Disease Prevention and Control

Conteúdos relacionados:

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Comentário no Twitter (fio – clique para saber mais)

#JustPublished!#ECDC and @EMA_News issue advice on fourth doses of mRNA #COVID19 vaccines.

Read the full joint statement: https://t.co/hBuOlrfKOD pic.twitter.com/aO5vSyYvTk

— ECDC (@ECDC_EU) April 6, 2022

 

---

Perspectiva | Um roteiro equitativo para acabar com a pandemia de COVID-19.

8 Abr, 2022 | 21:43h

An equitable roadmap for ending the COVID-19 pandemic – Nature Medicine

 

Comentário no Twitter

A Comment article in @NatureMedicine argues that the COVID-19 pandemic will end only with a renewed focus on equitable distribution of vaccines and therapeutics, responsive public health plans, and policies to protect the vulnerable. https://t.co/2cZShdqnY3

— Nature Portfolio (@NaturePortfolio) April 6, 2022

 

---

Recomendações da OMS para colaboração na resistência antimicrobiana.

8 Abr, 2022 | 21:40h

Strategic framework for collaboration on antimicrobial resistance – World Health Organization

Conteúdos relacionados:

Four priority actions to slow the silent pandemic of antimicrobial resistance.

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.

Perspective | The hidden epidemic: Antibiotic resistance is approaching a crisis point, and the world needs to act.

 

Comentário no Twitter

#DYK: Drug resistant organisms are found in people, animals, food, plants and the environment.
That's why WHO works in collaboration with @FAO, @OIEAnimalHealth & @UNEP to address #AntimicrobialResistance https://t.co/enhUb1jg2g pic.twitter.com/9elCBspx4y

— World Health Organization (WHO) (@WHO) April 6, 2022

 

---

Estudo observacional sugere que a 4ª dose da vacina da Pfizer forneceu proteção adicional contra doença grave em pacientes com 60 anos de idade ou mais durante a onda da variante Ômicron em Israel.

8 Abr, 2022 | 21:11h

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel – New England Journal of Medicine

Comentário: Mixed Bag for Fourth Dose of Pfizer Vaccine vs Omicron— Real-world data show less infection and severity, but long-term benefit less clear – MedPage Today (necessário cadastro gratuito)

Conteúdos relacionados:

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Comentário no Twitter

Just published @NEJM
4th dose vaccine protection in >620,000 people vs 3-doses in >620,000, all age 60+, Omicron wave, Israel
—4-fold lower rate of severe disease, no waning at 6 weeks
—2-fold lower rate of infection, rapidly wanedhttps://t.co/g8uGMXGHD6 pic.twitter.com/D7WHywTI1j

— Eric Topol (@EricTopol) April 5, 2022

 

---

Estudo de coorte retrospectiva | Queda na efetividade das vacinas Pfizer e CoronaVac contra COVID-19 na Malásia.

8 Abr, 2022 | 21:08h

Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study – International Journal of Infectious Diseases

 

Comentário no Twitter

@ICR_NIH RECoVam's
Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia in IJID.https://t.co/QwNSRQBKOq

• Against infections, both wane after 3-5 months
• Against ICU admission, CoronaVac wane
• Against death, both retain considerable effectiveness

— Dr Kalai Peariasamy (@drkalai61) March 22, 2022

 

---

Tendências globais, regionais e nacionais do consumo de analgésicos opioides de 2015 a 2019.

8 Abr, 2022 | 17:21h

Global, regional, and national trends in opioid analgesic consumption from 2015 to 2019: a longitudinal study – The Lancet Public Health

Comunicado de imprensa: Global disparities persist in opioid painkiller access – University College London

Comentário convidado: Closing the global pain divide: balancing access and excess – The Lancet Public Health

 

Comentário no Twitter (artigo e imagens sob licença de Creative Commons Attribution (CC BY 4.0)

Just Out @TheLancetPH 🚨
Global #opioids consumption increased from 2015 to 2019‼️#Disparities in opioid💊consumption remained, indicating potential inadequate access to essential pain relief in countries with low consumption🌐https://t.co/bkcdgLy3ZP pic.twitter.com/RUGl1gbiTw

— Gil Morgan (@weoncologists) April 1, 2022

 

---

Bilhões de pessoas ainda respiram um ar não saudável: novos dados da OMS.

6 Abr, 2022 | 13:00h

Comunicado de imprensa: Billions of people still breathe unhealthy air: new WHO data – World Health Organization

Relatório: WHO Air quality Database 2022

Comentários:

South-East Asia, Africa and Middle East are World’s Air Pollution Hot Spots in WHO’s Largest-Ever Data Release – Health Policy Watch

WHO says 99% of world’s population breathes poor-quality air – Associated Press

Conteúdo relacionado: New WHO Global Air Quality Guidelines aim to save millions of lives from air pollution.

 

Comentário no Twitter (fio – clique para saber mais)

Shocking!
99% – or almost the entire world's population breathes air with unhealthy levels of fine particulate matter & nitrogen dioxide, and threatens their health.
More: https://t.co/Llaj2wHk0V #HealthierTomorrow pic.twitter.com/QlHUP4iyS4

— World Health Organization (WHO) (@WHO) April 4, 2022

 

---

Perspectiva | As evidências sobre a 4ª dose das vacinas contra Covid & a questão complicada dos limites de idade.

6 Abr, 2022 | 12:53h

The Evidence On 4th Doses of Covid Vaccines & the Thorny Question of Age Thresholds – Absolutely Maybe Blog, by Hilda Bastian

Conteúdos relacionados:

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Comentário no Twitter

The evidence on 4th doses of Covid vaccines & the thorny question of age thresholds – 50? 55? 60? 65? 70? 75? 80? Each has been set by at least one country… | New @PLOS https://t.co/4tJ0o1fUC1

— Hilda Bastian, PhD (@hildabast) April 1, 2022

 

---